120 related articles for article (PubMed ID: 9392560)
21. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
22. Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis.
Robertson AG; Robertson C; Perone C; Clarke K; Dewar J; Elia MH; Hurman D; MacDougall RH; Yosef HM
Radiother Oncol; 1998 Aug; 48(2):165-73. PubMed ID: 9783888
[TBL] [Abstract][Full Text] [Related]
23. Linear quadratic model--estimation of alpha/beta ratio for mucosal reaction.
Chougule A; Supe SJ
Strahlenther Onkol; 1993 Jul; 169(7):427-30. PubMed ID: 8342116
[TBL] [Abstract][Full Text] [Related]
24. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma.
Fowler JF; Ritter MA
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):521-9. PubMed ID: 7751194
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy of advanced laryngeal cancer using three small fractions daily.
Bradley PJ; Morgan DA
Otolaryngol Head Neck Surg; 1991 Jun; 104(6):838-41. PubMed ID: 1908977
[TBL] [Abstract][Full Text] [Related]
26. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.
Suwinski R; Sowa A; Rutkowski T; Wydmanski J; Tarnawski R; Maciejewski B
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):399-412. PubMed ID: 12738315
[TBL] [Abstract][Full Text] [Related]
27. Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada.
Hendry JH; Roberts SA; Slevin NJ; Keane TJ; Barton MB; Agren-Cronqvist A
Radiother Oncol; 1994 Apr; 31(1):14-22. PubMed ID: 8041895
[TBL] [Abstract][Full Text] [Related]
28. Overall time in telecobalt therapy for T1 glottic carcinoma treated with 2 Gy per day.
Inoue T; Inoue T; Teshima T; Murayama S; Yamazaki H; Nose T; Tanaka E
Strahlenther Onkol; 1995 Aug; 171(8):475-7. PubMed ID: 7652672
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus: an alternative to conservation surgery.
Mendenhall WM; Parsons JT; Stringer SP; Cassisi NJ; Million RR
Int J Radiat Oncol Biol Phys; 1993 Dec; 27(5):1017-27. PubMed ID: 8262822
[TBL] [Abstract][Full Text] [Related]
30. A challenge to traditional radiation oncology.
Fowler JF; Tomé WA; Fenwick JD; Mehta MP
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1241-56. PubMed ID: 15519797
[TBL] [Abstract][Full Text] [Related]
31. Early results of radiotherapy for advanced laryngeal cancer using three small fractions per day.
Morgan DA; Bradley PJ; MacLennan KA
Acta Oncol; 1987; 26(6):437-40. PubMed ID: 3446242
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules.
Wyatt RM; Jones BJ; Dale RG
Br J Radiol; 2008 Jul; 81(967):549-63. PubMed ID: 18378526
[TBL] [Abstract][Full Text] [Related]
33. Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?
Garden AS; Forster K; Wong PF; Morrison WH; Schechter NR; Ang KK
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):322-8. PubMed ID: 12527044
[TBL] [Abstract][Full Text] [Related]
34. Late local recurrence after radiotherapy for tongue and early glottic carcinoma.
Inoue T; Inoue T; Teshima T; Murayama S; Nose T; Tanaka E; Yamazaki H; Koizumi M; Kagawa K; Ozeki S; Ikeda H
Strahlenther Onkol; 1996 Jun; 172(6):301-5. PubMed ID: 8677501
[TBL] [Abstract][Full Text] [Related]
35. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
[TBL] [Abstract][Full Text] [Related]
36. Dose, time, and fraction size issues for late effects in head and neck cancers.
Taylor JM; Mendenhall WM; Lavey RS
Int J Radiat Oncol Biol Phys; 1992; 22(1):3-11. PubMed ID: 1727126
[TBL] [Abstract][Full Text] [Related]
37. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers.
Robertson C; Robertson AG; Hendry JH; Roberts SA; Slevin NJ; Duncan WB; MacDougall RH; Kerr GR; O'Sullivan B; Keane TJ
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):319-29. PubMed ID: 9457816
[TBL] [Abstract][Full Text] [Related]
38. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments.
Visser AG; van den Aardweg GJ; Levendag PC
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):497-505. PubMed ID: 8567354
[TBL] [Abstract][Full Text] [Related]
39. Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity.
Kaanders JH; van Daal WA; Hoogenraad WJ; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 1992; 24(3):497-503. PubMed ID: 1399736
[TBL] [Abstract][Full Text] [Related]
40. 331 cases of clinically node-negative supraglottic carcinoma of the larynx: a study of a modest size fixed field radiotherapy approach.
Sykes AJ; Slevin NJ; Gupta NK; Brewster AE
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1109-15. PubMed ID: 10725620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
